Live Breaking News & Updates on நோவா மூலதனம் சர்வதேச

Stay updated with breaking news from நோவா மூலதனம் சர்வதேச. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings


Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “
Transaction”).
Transaction Highlights
Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments.
Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, as well as six patent applications.
Adelia contributes an expanding library of psychedelic derivative drug development candidates. The first lead compounds are expected to enter clinical studies in 2021, subject to receipt of approvals. ....

United States , Northeastern University , Brett Greene , Michaelg Palfreyman , Michael Palfreyman , Doug Drysdale , Alex Nivorozhkin , Eli Lilly , Brettj Greene , Development Officer , Cybin Corp , Nova Capital International , Cybin Inc , Drug Administration , Cybin Us Holdings Inc , Health Canada , Chief Executive Officer , Chief Strategy Officer , Drug Discovery , Chief Operating Officer , Chief Scientific , Chief Research , Chief Innovation , Adelia Shareholders , Classb Share , Classb Shares ,

CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings


Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “
Transaction”).
Transaction Highlights
Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments.
Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, as well as six patent applications.
Adelia contributes an expanding library of psychedelic derivative drug development candidates. The first lead compounds are expected to enter clinical studies in 2021, subject to receipt of approvals. ....

United States , Northeastern University , Brett Greene , Michaelg Palfreyman , Michael Palfreyman , Doug Drysdale , Alex Nivorozhkin , Eli Lilly , Brettj Greene , Development Officer , Cybin Corp , Nova Capital International , Cybin Inc , Drug Administration , Cybin Us Holdings Inc , Adelia Therapeutics Inc , Health Canada , Adelia Therapeutics , Chief Executive Officer , Chief Strategy Officer , Drug Discovery , Chief Operating Officer , Chief Scientific , Chief Research , Chief Innovation , Adelia Shareholders ,